SCHEMBL15037306

SCHEMBL15037306

CC(C)(C)c1ccc(-c2cnc(-c3ccc(C[C@H](NC(=O)c4ccc(OC(F)(F)F)cc4)C(=O)O)cc3)nc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR132 Q9UNW8 3/20 0.52
▸ EPHX2 P34913 2/20 0.52
▸ NR1H4 Q96RI1 1/20 0.52
▸ KLKB1 P03952 1/20 0.47
▸ GCGR P47871 2/20 0.47
▸ TRPV1 Q8NER1 1/20 0.47
▸ ADCY6 O43306 1/20 0.47
▸ ADCY3 O60266 1/20 0.47
▸ ADCY9 O60503 1/20 0.47
▸ ADCY5 O95622 1/20 0.47
▸ ADCY8 P40145 1/20 0.47
▸ ADCY7 P51828 1/20 0.47
▸ ADCY2 Q08462 1/20 0.47
▸ ADCY1 Q08828 1/20 0.47
▸ ADCY4 Q8NFM4 1/20 0.47
▸ PPARG P37231 1/20 0.46
▸ PPARA Q07869 1/20 0.46
▸ FPR2 P25090 1/20 0.46
▸ USP30 Q70CQ3 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22449277 0.90 MME (0.49) GPR132KDM4EKDM4ACA2PDK1
SCHEMBL15037189 0.90 MME (0.49) GPR132KDM4EKDM4ACA2PDK1
SCHEMBL22449044 0.90 CA2 (0.57) GPR132EPHX2NR1H4KDM4EKDM4A
SCHEMBL22449235 0.90 CA2 (0.57) GPR132EPHX2NR1H4KDM4EKDM4A
SCHEMBL15037198 0.90 CA2 (0.57) GPR132EPHX2NR1H4KDM4EKDM4A
SCHEMBL15037187 0.90 CA2 (0.57) GPR132EPHX2NR1H4KDM4EKDM4A
SCHEMBL22449204 0.89 KIFC1 (0.50) GPR132EPHX2PPARGPPARAFPR2
SCHEMBL15037301 0.89 KIFC1 (0.50) GPR132EPHX2PPARGPPARAFPR2
SCHEMBL15037297 0.89 KIFC1 (0.50) GPR132EPHX2PPARGPPARAFPR2
SCHEMBL22449146 0.89 KIFC1 (0.50) GPR132EPHX2PPARGPPARAFPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-2791112-B1 CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES CELGENE INT II SÀRL (CH) 2020-09-23 — — EP disclosed
EP-3230276-B1 GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-09-02 — — EP disclosed
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
US-10034886-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2018-07-31 — — US disclosed
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2018-01-25 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-9795613-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-10-24 — — US disclosed
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-08-11 — — US disclosed
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-07-28 — — US disclosed
US-9187522-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2015-11-17 — — US disclosed
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-02-05 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
US-8778923-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2014-07-15 — — US disclosed
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-07-11 — — US disclosed
WO-2013090454-A2 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160228450-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R GPR132 178/4885EPHX2 4296/4885NR1H4 1028/4885
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R GPR132 178/4885EPHX2 4296/4885NR1H4 1028/4885
US-20160214993-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R GPR132 178/4885EPHX2 4296/4885NR1H4 1028/4885
US-20180021346-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R GPR132 178/4885EPHX2 4296/4885NR1H4 1028/4885
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R GPR132 156/4885EPHX2 4053/4885NR1H4 824/4885
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R GPR132 156/4885EPHX2 4053/4885NR1H4 824/4885
US-10034886-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR GPR132 228/4885EPHX2 4326/4885NR1H4 886/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR GPR132 228/4885EPHX2 4326/4885NR1H4 886/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R GPR132 178/4885EPHX2 4296/4885NR1H4 1028/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback